Plasma MicroRNAs as Sensitive and Specific Biomarkers of Tissue Injury

Laterza, Omar; Lim, Lee P.; Garrett-Engele, Philip W.; Vlasáková, Kateřina; Muniappa, Nagaraja; Tanaka, Wesley; Johnson, Jason M.; Sina, Joseph F.; Fare, Thomas L.; Sistare, Frank D.; Glaab, Warren E.

doi:10.1373/clinchem.2009.131797

Cited by 569 publications

(449 citation statements)

References 24 publications

Supporting

Mentioning

428

Contrasting

Unclassified

Order By: Relevance

“…Recent progress in understanding small RNA biology and physiology has brought new and exciting perspectives about the regulation of reproductive function by miRNAs. In addition, the clinical relevance of miRNAs has steadily grown over the past few years particularly in relation to their significant potential as biomarkers of tissue function (Laterza et al 2009, Schwarzenbach et al 2011. Also, the possibility that miRNAs associated with certain clinical diseases, including ovarian diseases (Yang et al 2012), could be therapeutically targeted has generated enormous interest within medical communities (Pfeifer & Lehmann 2010).…”

Section: Discussionmentioning

confidence: 99%

Involvement of miRNAs in ovarian follicular and luteal development

Donadeu¹,

Schauer²,

Sontakke³

2012

Journal of Endocrinology

159

110

View full text Add to dashboard Cite

Although much progress has been made in the genetic dissection of biological networks involved in follicular/luteal development in the mammalian ovary, the gene regulation mechanisms involved are still poorly understood. Over the last 10 years, miRNAs have emerged as master regulators of tissue growth and differentiation in animals. However, compared with other body tissues, little is still known about the functional involvement of miRNAs in the ovary. Several studies have identified miRNA populations specifically associated with the development of follicles and corpora lutea, particularly in relation to the follicular-luteal transition, and the functional involvement of some of these miRNAs has been characterised in vitro and/or in vivo. Specifically, three different miRNAs, miR-224, miR-378 and miR-383, have shown to be involved in regulating aromatase expression during follicle development. In addition, miR-21 has been identified as promoting follicular cell survival during ovulation, and pro-angiogenic miR-17-5p and let-7b were shown to be necessary for normal development of the corpus luteum. Experimental evidence for the involvement of several other miRNAs in different aspects of follicle/luteal development has also been obtained. In addition, many of these studies exemplify the challenges associated with identifying physiologically relevant targets of ovarian miRNAs. Continuous advances in this field will be considerably facilitated by progress in understanding miRNA physiology in other body systems and will eventually lead to a much better understanding of the control of follicular/luteal development. In turn, through the potential offered by miRNA diagnostics and miRNA therapeutics, this new knowledge should bring considerable benefits to reproductive medicine.

show abstract

Section: Discussionmentioning

confidence: 99%

Involvement of miRNAs in ovarian follicular and luteal development

Donadeu¹,

Schauer²,

Sontakke³

2012

Journal of Endocrinology

159

110

View full text Add to dashboard Cite

show abstract

“…miR-124 in the brain, miR-133a in the heart, or miR-122 in the liver, the latter being well explored in regard to drug overdose-induced hepatotoxicity (Laterza et al 2009). Tissue-specific miRNAs can be relevant biomarkers for regulatory toxicology, even more so since they are stable and can be found in all body fluids.…”

Section: And University Of Surrey Ukmentioning

confidence: 99%

Advancing the use of noncoding RNA in regulatory toxicology: Report of an ECETOC workshop

Aigner¹,

Buesen²,

Gant³

et al. 2016

Regulatory Toxicology and Pharmacology

View full text Add to dashboard Cite

The European Centre for the Ecotoxicology and Toxicology of Chemicals (ECETOC) organised a workshop to discuss the state-of-the-art research on noncoding RNAs (ncRNAs) as biomarkers in regulatory toxicology and as analytical and therapeutic agents. There was agreement that the abundance of data obtained from ncRNA expression profiling requires careful evaluation to determine the utility of specific ncRNAs for regulatory toxicology. To advance the use of ncRNA in regulatory toxicology, the following research priorities were identified: (1) Conduct comprehensive literature reviews to identify candidate ncRNAs for further assessment as potential biomarkers of toxicity and areas of toxicology where ncRNA expression profiling can address prevailing scientific deficiencies.(2) Develop consensus on how to conduct and report ncRNA expression profiling in a toxicological context to support applicability for regulatory decision-making. (3) Conduct experimental projects to evaluate the toxicological relevance of the expression profiles of selected ncRNAs. As necessary, retrospective analyses (e.g. from surplus samples from control groups from regulatory studies) can be supplemented with new (90-day) rat oral toxicity studies. These projects should aim at establishing physiological ncRNA expression profiles including the biological variability of healthy individuals. To substantiate the relevance of key ncRNAs for cell homeostasis or pathogenesis, molecular events should be linked with substance-induced apical effects in a dose-dependent manner. Applying a holistic approach, knowledge on ncRNAs, and relevant information from 'omics and epigenetics technologies, should be integrated into adverse outcome pathways to improve the understanding of the functional roles of ncRNAs within a regulatory context.

show abstract

“…Wide spectrum of skeletal muscle-and cardiac-specific miRNAs (miRNA-12, miRNA-133a, miRNA-124 and miRNA 208) miRNAs has been investigated as circulating biomarkers of myotoxicity [46]. Because several miRNAs have exhibit tissue specificity, stability in extracellular space, high conservation between preclinical test species, and might express as response on direct tissue injury, it has been suggested that signature of microRNAs might be useful as biomarkers of cardiac injury [47,48].…”

Section: Micrornasmentioning

confidence: 99%

Determination of early tumoricidal drug-induced cardiotoxicity with biological markers

Berezin¹

2016

J Transl Sci

View full text Add to dashboard Cite

Cardiotoxicity due to tumoricidal drug use is defined as an asymptomatic reduction in left ventricular (LV) ejection fraction (EF) of ≥ 10% to <55% or as a reduction of the LVEF of ≥ 5% to <55% with symptoms of heart failure (HF). The implementation in routine practices the highly tumoricidal anthracycline drugs, taxanes, and trastuzumab cause progressive LV dysfunction and symptomatic HF in dose-dependent manner. Despite there is potent reversibility of tumoricidal drug-induced cardiotoxicity, this adverse effect frequently consists continuously and might lead to limited response to medical treatment and worse survival sufficiently. The aim of the mini review is consideration the clinical evidence that supports the use of cardiac biomarkers for early detection of cardiotoxicity. The review is reported that the identification of cancer patient with increased risk of early cardiotoxicity would allow not only prevention and diagnosis of chemotherapy related cardiotoxicity but also administration of optimal dose and duration of chemotherapy. The predictive role of brain natriuretic peptides, cardiac troponins, microRNAs, S100A1 and inflammatory biomarkers (C-reactive protein) is discussed.

show abstract

Plasma MicroRNAs as Sensitive and Specific Biomarkers of Tissue Injury

Abstract: These results demonstrate that tissue-specific miRNAs may serve as diagnostically sensitive plasma biomarkers of tissue injury.

Cited by 569 publications

References 24 publications

Involvement of miRNAs in ovarian follicular and luteal development

Involvement of miRNAs in ovarian follicular and luteal development

Advancing the use of noncoding RNA in regulatory toxicology: Report of an ECETOC workshop

Determination of early tumoricidal drug-induced cardiotoxicity with biological markers

Contact Info

Product

Resources

About